Dublin, Ireland-based biopharma Carrick Therapeutics has licensed exclusive global rights to develop and commercialise BTG’s targeted ovarian cancer drug BTG945. The investigational drug, a combination of the targeting folate receptor α (FRα) and inhibiting thymidylate synthase, will now be referred to ...